Tizanidine is a prescription muscle relaxant used for spasticity, and employees and employers both ask the same question when it shows up on a medication list before a workplace test: will it trigger a positive, or interfere with the result in some other way. The short answer is that tizanidine is not a federally controlled substance and it is not a target analyte on any standard immunoassay panel. A lab can detect it, but only with a test specifically designed to look for it. This article covers what tizanidine is, whether it is scheduled, what standard panels actually test for, what the published evidence says about cross reactivity, how confirmation testing resolves a presumptive positive, the Medical Review Officer process, and what to do with a disputed result.
What tizanidine is and how it is classified
Tizanidine is described on its current current prescribing information as a central alpha 2 adrenergic agonist indicated for the treatment of spasticity. It works in the central nervous system rather than at the muscle itself, and its labeling lists dry mouth, somnolence, asthenia, and dizziness among the most common adverse reactions. The label also warns against combining tizanidine with moderate or weak CYP1A2 inhibitors because the combination can cause hypotension, bradycardia, or excessive drowsiness. The full current prescribing information is available through the National Library of Medicine's DailyMed database, and the FDA's approval record for the branded version, Zanaflex, can be reviewed through Drugs@FDA.
Tizanidine does not appear on the Drug Enforcement Administration's published list of controlled substances. The DEA maintains a current alphabetical listing of every substance scheduled under the Controlled Substances Act, covering Schedule I through Schedule V, and tizanidine is not one of the entries on that list, which is published at deadiversion.usdoj.gov. That means tizanidine carries no DEA scheduling restriction of its own, although it still requires a prescription to obtain and use legally, and the prescribing label itself carries no controlled substance designation.
Is tizanidine a target on standard workplace panels
Standard urine immunoassay panels, whether a 5 panel, 10 panel, or 12 panel configuration, screen for specific drug classes rather than for every medication a person might be taking. Under the federal testing rules that govern Department of Transportation programs, the drugs and drug classes a laboratory must screen for are listed at 49 CFR 40.85, and they are marijuana metabolites, cocaine metabolites, phencyclidine, specific opioids such as codeine, morphine, hydrocodone, hydromorphone, oxycodone, and oxymorphone, and amphetamine type stimulants including methamphetamine and MDMA. Tizanidine is not chemically related to any of those classes and is not one of the analytes a screening antibody on a standard cup or dip card is built to bind. The current regulatory text is available in the official Code of Federal Regulations publication from the Government Publishing Office, which can be reviewed at govinfo.gov, 49 CFR Part 40.
Extended non DOT panels, including some 10 panel and 12 panel configurations, add analytes such as benzodiazepines, barbiturates, methadone, and propoxyphene. Tizanidine is not one of the drugs those extended immunoassay classes are designed to detect either. A standard panel is not expected to produce a presumptive positive from tizanidine use under any of its listed drug classes.
| Panel type | Typical analytes targeted | Detects tizanidine |
|---|---|---|
| 5 panel | Amphetamines, cocaine, opiates, PCP, THC | No |
| 10 panel | Above plus benzodiazepines, barbiturates, methadone, methaqualone, propoxyphene | No |
| 12 panel | 10 panel analytes plus additional opioid or stimulant targets depending on configuration | No |
| Targeted lab test for tizanidine | Tizanidine specifically, ordered by name | Yes, when ordered |
What the published cross reactivity evidence actually says
Cross reactivity occurs when a substance unrelated to the intended target binds the antibody in an immunoassay closely enough to trigger a presumptive positive for the wrong drug class. Reviewers track documented cross reactants for assay classes such as amphetamines and opioids because certain other medications have a known history of producing false positives on those specific screens. Tizanidine does not have that kind of documented record. There is no published cross reactivity data showing that tizanidine triggers a presumptive positive on standard amphetamine, opiate, benzodiazepine, PCP, or THC immunoassays, and the current prescribing label on DailyMed contains no section addressing drug screen interference. In plain terms, there is no published cross reactivity between tizanidine and the drug classes targeted by standard workplace panels. If new evidence emerges, the manufacturer's labeling and federal drug information resources would be the places that evidence would first appear, so this absence of evidence should be read as the current state of the record rather than a permanent promise.
Clonidine and the alpha 2 agonist class
Tizanidine belongs to the same broad pharmacologic family as clonidine, another prescription alpha 2 adrenergic agonist used for blood pressure and other conditions. The two drugs are prescribed for different indications and are not interchangeable, but employers sometimes ask about both because they share a mechanism and a sedation profile. Clonidine raises its own separate drug testing questions, which are covered in more detail in our related article on clonidine linked below. Neither drug is a standard panel target, and neither should be assumed to behave like the other without checking the specific label and testing context involved.
Why GC/MS and LC/MS confirmation still matters
Any presumptive positive from an immunoassay cup or dip card, regardless of drug class, is a screening result and not a final determination. Gas chromatography mass spectrometry or liquid chromatography mass spectrometry confirmation testing identifies the specific molecule present in a sample rather than relying on antibody binding, which can occasionally react to unrelated compounds. Because tizanidine is not a target of standard immunoassay panels, confirmation testing would not ordinarily be triggered by tizanidine use on a routine panel. Confirmation becomes relevant only if a lab or employer has separately ordered a targeted test for tizanidine, or if a different analyte on the panel produced a presumptive positive that needs to be resolved. Confirmation is what separates a preliminary screening signal from a verified, reportable result, and it is standard practice for any non negative screen.
The MRO review and prescription documentation step
For employers running a program under federal rules, including Department of Transportation regulated testing, a non negative screening result goes to a Medical Review Officer before it is reported to the employer. Under the procedures codified at 49 CFR Part 40, Subpart G, the MRO contacts the tested individual, reviews the laboratory result, and considers any legitimate medical explanation, including a valid prescription, before classifying a result as verified positive, cancelled, or negative. The full subpart governing MRO duties, interviews, and verification decisions is part of the same Code of Federal Regulations text available at govinfo.gov. An employee taking tizanidine under a doctor's care should be ready to provide prescription documentation if any question comes up during MRO review, even though tizanidine is not expected to trigger a panel result on its own. The MRO process exists precisely to resolve situations like a prescribed medication being questioned or a lab flag that needs clinical context before anything is reported to the employer.
Sedation and safety sensitive work
Separate from the drug testing question, tizanidine's labeling carries clear warnings about somnolence, dizziness, and asthenia, which matter for employees in safety sensitive roles such as driving, operating machinery, or working at heights. Fitness for duty concerns tied to sedating medications are a workplace safety issue that an employer may need to address directly with the employee, and where a role is covered by Department of Transportation physical qualification standards, that conversation may also involve the medical examiner who certifies the driver. This is a separate question from whether tizanidine would ever appear on a drug test, and employers should not conflate the two. Any fitness for duty decision should involve the employee's prescriber and, where appropriate, legal counsel, since obligations can vary by state and by the specific safety sensitive duties involved.
What employers should do with a disputed result
If an employee reports taking tizanidine and a screening result comes back non negative for an unrelated analyte, the appropriate step is to route the result through the standard MRO review process rather than assume tizanidine caused it, since there is no documented pathway for it to trigger a false positive on a standard panel. The employee's prescription records and the MRO's independent medical review are the correct channels for resolving the question, and GC/MS or LC/MS confirmation resolves any doubt about the specific substance detected. Employers generally should not make adverse employment decisions based on an unconfirmed screening result alone, and testing policies in this area should be reviewed with qualified counsel since practices and protections vary by state and by whether the employer is subject to federal testing rules.
Frequently asked questions
Does tizanidine show up on a standard 5 panel or 10 panel drug test?
No. Standard panels target drug classes such as amphetamines, opiates, cocaine metabolite, PCP, THC, and in extended panels benzodiazepines and barbiturates. Tizanidine is not one of the analytes those immunoassay antibodies are designed to detect.
Is tizanidine a controlled substance?
No. Tizanidine does not appear on the DEA's published controlled substance schedules. It is a prescription drug but carries no DEA scheduling of its own.
Can tizanidine cause a false positive on a drug test?
There is no published cross reactivity evidence showing tizanidine triggers a false positive on standard amphetamine, opiate, benzodiazepine, PCP, or THC immunoassays. If a question does arise, GC/MS or LC/MS confirmation and the Medical Review Officer process are the correct ways to resolve it.
Is tizanidine related to clonidine for drug testing purposes?
They share a pharmacologic class, both being alpha 2 adrenergic agonists, but they are different drugs with different indications. Neither is a standard panel target, and each should be evaluated on its own label and evidence rather than assumed to behave like the other.
How would a lab test for tizanidine specifically?
A lab can test for tizanidine only through a targeted analysis ordered to look for that specific drug. Standard workplace panels do not include it as a target analyte, so detecting tizanidine requires a separate, specifically requested lab test.
What should an employee do if they take prescribed tizanidine and get tested?
Keep prescription documentation available. If a Medical Review Officer contacts the employee about any non negative result, providing the prescription and prescriber information allows the MRO to complete its review under 49 CFR Part 40.
Related reading: Does Clonidine Show Up on a Drug Test? covers the related alpha 2 agonist class in more detail, and the Medical Review Officer process explainer walks through how a non negative result is reviewed before it reaches an employer.
Employers building or updating a testing program can review American Screening Corporation's drug test cup collection for panel configurations and cutoff options.
This article is general information about drug testing science and workplace procedure. It is not legal advice or medical advice. Employers should consult qualified counsel for policy decisions, and individuals should consult their prescribing provider for any medical questions.
